Structure Therapeutics Inc (GPCR) Stock Price, Quote & News

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 1978

Website: structuretx.com

Address:

601 Gateway Boulevard, Suite 900, South San Francisco, United States

Meltingflame Oct. 27 at 7:39 PM

$GPCR Wow! Had to check if there was news... None. I like it all the sane. We expect news this qtr.

0 · Reply

fx_lux99 Oct. 27 at 6:18 PM

$GPCR

0 · Reply

topstockalerts Oct. 27 at 6:15 PM

$GPCR Is it going higher? Comment below...

0 · Reply

judgeyoung2 Oct. 27 at 5:31 PM

$GPCR Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.

0 · Reply

ZacksResearch Oct. 24 at 4:58 PM

$NVO vs. $GPCR — Which obesity play has the edge right now? Novo Nordisk is dealing with headwinds and leadership changes, while Structure Therapeutics is gearing up for key obesity-drug data later this year — a make-or-break moment for investors watching the space. Full comparison and outlook here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-teaser-17580&ADID=SYND_STOCKTWITS_TWEET_2_2776570_TEASER_17580

0 · Reply

ZacksResearch Oct. 24 at 3:58 PM

$NVO vs. $GPCR — Which is the better bet in obesity treatment? 🤔 NVO faces headwinds with competition from Eli Lilly and leadership transitions, while GPCR is gearing up for pivotal study data releases. Despite being a clinical-stage biotech with no marketed products, GPCR carries a Zacks Rank #3 (Hold) compared to NVO’s Zacks Rank #4 (Sell). Opportunity assessment here 👉 https://www.zacks.com/stock/news/2776570/nvo-vs-gpcr-which-obesity-stock-is-the-better-buy-right-now?cid=sm-stocktwits-2-2776570-body-17559&ADID=SYND_STOCKTWITS_TWEET_2_2776570_BODY_17559

2 · Reply

Quantumup Oct. 23 at 2:30 PM

Cantor has Strong Words on $VKTX's Oral: Viking also mentioned on the call that a manuscript for the Phase 2 VENTURE study was accepted for publication in a leading medical journal and should be published in early-2026. $GPCR $LLY $NVO $AMGN PFE MRK 👀Positive and Strong Words from Seedhouse on the Oral: VENTURE Phase 2 data publication in leading medical journal: Early-2026 (will discharge any lingering questions about strength of data compared to tirzepatide and others).😱

0 · Reply

Quantumup Oct. 23 at 12:02 PM

Wow, Seedhouse/Cantor just called the $VKTX (Overweight; $105 PT) 3Q update transformative and said that "this was the most bullish update Viking has given since we started covering the stock more than 7 years ago." $GPCR $LLY $NVO $AMGN PFE MRK Cantor additionally said: VKTX just crystallized five critically important data catalysts in the next 24 months, and Viking affirmed cash on hand of >$700M was sufficient to get through all of them.

0 · Reply

biolover Oct. 23 at 10:20 AM

$AMGN $GPCR $LLY $NVO $VKTX Someone finally reaching this conclusion about $VKTX oral phase 3 size “We also believe the oral Phase 3 program could enroll fewer patients than subcutaneous by leveraging the ~5,500 patient safety databases from the VANQUISH studies.”

1 · Reply

Quantumup Oct. 23 at 10:14 AM

BTIG reiterated $VKTX Buy/$125 $GPCR $LLY $NVO $AMGN PFE MRK BTIG said in its note:

1 · Reply

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Jun 23, 2025, 6:10 PM EDT - 4 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Jun 20, 2025, 7:30 PM EDT - 4 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Apr 14, 2025, 10:49 AM EDT - 7 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Mar 27, 2025, 7:40 AM EDT - 7 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Mar 24, 2025, 6:26 PM EDT - 7 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:23 PM EDT - 7 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Mar 20, 2025, 9:28 AM EDT - 7 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Jan 30, 2025, 8:30 AM EST - 9 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 6, 2025, 2:53 PM EST - 10 months ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Dec 17, 2024, 4:01 PM EST - 11 months ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 5, 2024, 6:17 PM EST - 11 months ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Mar 9, 2024, 2:30 AM EST - 1 year ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Mar 8, 2024, 4:05 PM EST - 1 year ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

Mar 8, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Jan 17, 2024, 3:40 PM EST - 1 year ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX TERN

Dec 20, 2023, 11:17 AM EST - 2 years ago

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

LLY NVO ALT AMGN VKTX

Dec 18, 2023, 11:56 AM EST - 2 years ago

Structure Therapeutics reports promising results for weight-loss pill

Dec 18, 2023, 11:29 AM EST - 2 years ago

New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data.

Dec 18, 2023, 10:37 AM EST - 2 years ago

Structure's diabetes pill misses weight-loss expectations in mid-stage trial

Dec 18, 2023, 8:04 AM EST - 2 years ago

Structure Therapeutics stock plunges on new GLP-1 drug data

Dec 18, 2023, 7:30 AM EST - 2 years ago

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

Nov 14, 2023, 4:10 PM EST - 2 years ago

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Oct 3, 2023, 11:28 PM EDT - 2 years ago

Structure Therapeutics: Tipping The Scales In Obesity Management

Sep 29, 2023, 6:26 PM EDT - 2 years ago

Final Trades: Rivian, Pfizer, Treasury Bonds and more

PFE RIVN TLT

Sep 29, 2023, 12:02 PM EDT - 2 years ago

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Sep 29, 2023, 10:15 AM EDT - 2 years ago

Structure Therapeutics surges on promising early stage obesity drug data

Sep 29, 2023, 8:02 AM EDT - 2 years ago

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

Sep 29, 2023, 7:32 AM EDT - 2 years ago

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

Sep 29, 2023, 7:30 AM EDT - 2 years ago

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Meltingflame Oct. 27 at 7:39 PM

$GPCR Wow! Had to check if there was news... None. I like it all the sane. We expect news this qtr.

0 · Reply

fx_lux99 Oct. 27 at 6:18 PM

$GPCR

0 · Reply

topstockalerts Oct. 27 at 6:15 PM

$GPCR Is it going higher? Comment below...

0 · Reply

judgeyoung2 Oct. 27 at 5:31 PM

$GPCR Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.

0 · Reply

ZacksResearch Oct. 24 at 4:58 PM

0 · Reply

ZacksResearch Oct. 24 at 3:58 PM

2 · Reply

Quantumup Oct. 23 at 2:30 PM

0 · Reply

Quantumup Oct. 23 at 12:02 PM

0 · Reply

biolover Oct. 23 at 10:20 AM

1 · Reply

Quantumup Oct. 23 at 10:14 AM

BTIG reiterated $VKTX Buy/$125 $GPCR $LLY $NVO $AMGN PFE MRK BTIG said in its note:

1 · Reply

Quantumup Oct. 22 at 10:45 AM

Oppenheimer⬇️ $TERN's PT to $17 from $20 and reiterated at Outperform after removing TERN-601 from its model—Reminds Investors that Its Investment Thesis has Always Focused on TERN-701 in CML. $VKTX $GPCR $LLY $NVO Oppenheimer said: Following 12 weeks of treatment, TERN-601 showed an up to 4.6% placebo-adjusted weight loss, which was accompanied by a relatively high AE-related discontinuation rate of ~12% across all treatment cohorts. Additionally, three participants had Grade 3 liver enzyme elevations during the follow-up period post-treatment. As a result, it is not surprising that the company will not advance TERN-601. As a reminder, our investment thesis on TERN has always focused on TERN-701 in CML. The TERN-601 termination helps refocus investor attention on TERN-701, as we view the upcoming Ph1 CARDINAL readout in 4Q25 as a key catalyst. We removed TERN-601 from our model driving our new $17 PT (vs. prior $20).

1 · Reply

Quantumup Oct. 15 at 12:08 PM

Truist y'day after the close🏁 $TERN Buy/$20 $NVS $VKTX $GPCR $LLY NVO Truist said in its TERN initiation: Key investment points - 1) Potential best-in-class lead asset w/ promising Ph1 / preclinical data in rare blood cancer, a near ~$1B opportunity; 2) 2nd asset oral GLP-1 agonist derisked by approved drugs; potential to be safe oral option in obesity; 3) Partnerable assets supported by early stage data in multibillion metabolic opportunity like MASH and obesity; 4) Reprioritization to oncology reflects more focused and strategically feasible pivot, in our view; 5) Unadj 2036 peak market opportunity for lead asset $1.X.7B+/~$900M in peak adj revenues to TERN, not reflected at current levels, in our view.

0 · Reply

Meltingflame Oct. 13 at 7:37 PM

$GPCR News is due this quarter. Patiently waiting. If all goes well, easy double from here.

1 · Reply

twincam Oct. 11 at 9:35 PM

$GPCR GPCR (Structure Therapeutics) buyout scenario: • 🧪 Asset value: GPCR develops an oral GLP-1, a highly strategic obesity/diabetes drug class. • 📅 Catalyst: ACCESS topline data expected Q4 2025. • 🧠 Potential acquirers: AstraZeneca, Sanofi, and Merck & Co. are the most likely. Pfizer is less likely after its Metsera acquisition. • 📈 Valuation range: • Pre-data fair takeout: $39–50/share (30–60% premium) • Post-strong data fair takeout: $55–65+/share (up to 120% premium possible) • 🏁 Why high interest: Few oral GLP-1 targets remain, strong strategic fit for companies without a GLP-1 franchise. 👉 Bottom line: GPCR is well-positioned as a prime M&A target heading into 2025–2026, especially post-data.

1 · Reply

twincam Oct. 11 at 9:30 PM

$GPCR GPCR walking quiet while the giants circle the pond 🐊 ACCESS topline Q4 ‘25. Oral GLP-1 could be the real bait. Watch the usual suspects: $AZN, $SNY, $MRK 👀💊

0 · Reply

SendingTheWolf Oct. 8 at 4:35 PM

$GPCR Blind speculation following $VKTX with no data yet.

1 · Reply

Quantumup Oct. 8 at 12:29 PM

Citizens reiterated $TERN Market Outperform-$20 and said, TERN is positioning its oral GLP-1 as differentiated on safety, based on differentiated PKPD dynamics in the gut. $GPCR $LLY $PFE Citizens JMP went on to say:

0 · Reply

optn_trader Oct. 7 at 11:55 AM

$VKTX $GPCR $PFE $MRK

0 · Reply

Market Cap	1.52B
Revenue (ttm)	0.00
Net Income (ttm)	-122.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	704,800
Avg Vol	1,040,702
Day's Range	N/A - N/A
Shares Out	57.60M
Stochastic %K	15%
Beta	-1.65
Analysts	Strong Sell
Price Target	$76.00